Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236593 | 0.74 | PLAT (0.34) | PLATKDM4EMAPTTHRBELANE | |
| SCHEMBL6833620 | 0.74 | GPR119 (0.32) | PLATKDM4EMAPTTHRBKLK7 | |
| SCHEMBL3073012 | 0.68 | PLAT (0.35) | PLATKDM4EMAPTTHRBELANE | |
| SCHEMBL3729457 | 0.66 | PLAT (0.34) | PLATKDM4EMAPTTHRBALDH1A1 | |
| SCHEMBL4242555 | 0.66 | PLAT (0.35) | PLATKDM4EMAPTTHRBELANE | |
| SCHEMBL1420419 | 0.65 | GPR119 (0.33) | PLATKDM4EMAPTTHRBGPR119 | |
| SCHEMBL1847230 | 0.64 | PLAT (0.33) | PLATKDM4EMAPTTHRBGPR119 | |
| SCHEMBL1849220 | 0.64 | PLAT (0.32) | PLATKDM4EMAPTTHRB | |
| SCHEMBL21045970 | 0.63 | PLAT (0.36) | PLATKDM4EMAPTTHRBGPR119 | |
| SCHEMBL30853294 | 0.62 | CHRM2 (0.54) | GPR119CHRM2CHRM1CHRM3PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | PLAT 1253/4885KDM4E 2714/4885MAPT 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.